LRRK2 reduces the sensitivity to TKI and PD-1 blockade in ccRCC via activating LPCAT1
- 22 March 2025
- journal article
- research article
- Published by Springer Nature in Oncogene
- Vol. 44 (22) , 1761-1776
Abstract
Tyrosine kinase inhibitor (TKI) and immune checkpoint inhibitor (ICI) combination therapy is emerging as a major therapeutic strategy for advanced clear cell renal cell carcinoma (ccRCC). To define the druggable targets for improvement of TKI and ICI combination therapy in ccRCC, we analyzed a commercial protein kinase inhibitor dataset and a public ccRCC dataset and identified LRRK2 as a potential candidate that can be targeted by a small molecule inhibitor. We demonstrated that LRRK2 was transcriptionally upregulated by HIF2A and enabled to drive proliferation of ccRCC cells in a manner independent of its kinase activity. LRRK2 inhibits the RBX1-mediated degradation of lipid metabolism modulator LPCAT1 to reducing the sensitivity to TKI and PD-1 blockade in ccRCC. Specifically, LRRK2/LPCAT1 upregulated IL-1β expression levels through AKT and also increased IL-1β shearing by activating inflammasome. To target the kinase-independent activity of LRRK2, we developed an LR-protac and showed that LR-protac decreased LRRK2 protein level and enhanced the antitumor effect of PD-1 blockade and TKI in ccRCC. These data indicate that LRRK2 is a viable target for improvement of the efficacy of PD-1 blockade and TKI in ccRCC.Keywords
This publication has 68 references indexed in Scilit:
- Pterostilbene and 6-shogaol exhibit inhibitory effects on sunitinib resistance and motility by suppressing the RLIP76-initiated Ras/ERK and Akt/mTOR pathways in renal cancer cellsEuropean Journal of Pharmacology, 2024
- Role of NLRP3 inflammasome-mediated neuronal pyroptosis and neuroinflammation in neurodegenerative diseasesInflammation Research, 2023
- Overexpressed FAM111B degrades GSDMA to promote esophageal cancer tumorigenesis and cisplatin resistanceCellular Oncology, 2023
- LRRK2 and Parkinson's disease: from genetics to targeted therapyAnnals of Clinical and Translational Neurology, 2023
- LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's DiseaseMovement Disorders, 2023
- MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancerCancer Cell, 2022
- The tumour microenvironment and metabolism in renal cell carcinoma targeted or immune therapyJournal of Cellular Physiology, 2020
- European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 UpdateEuropean Urology, 2019
- The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular TumoursEuropean Urology, 2016
- The InflammasomesCell, 2010